European Journal of Pharmaceutical Sciences
Elsevier BV · NL · ISSN 09280987
趨勢摘要
Publication volume tightened while average citedness edged up.
Output shrank while citation impact rose. If you prioritise visibility per paper, this trend is relevant to your choice. Field-weighted citation impact moved from 1.89 to 1.91. Expect modestly higher average attention for articles here than in many places. RNA Interference and Gene Delivery rose from 2.0% to 5.4% of what the journal runs. Consider submitting RNA interference work when seeking topical fit. Gold open access accounts for 100.0%. Be prepared for article processing charges typical of full open access venues.
引用指標
以 Scopus 與 OpenAlex 的引用圖譜為基礎。本站不提供 Clarivate 的 JCR 影響係數(Impact Factor)。
發表量與被引用表現
看看發表量成長時,被引用表現是否跟著提升。
主題變化
比較近 24 個月(2024-09 – 2026-08)與再往前 24 個月(2022-09 – 2024-08)的佔比。
- RNA Interference and Gene Delivery2.0%→5.4%+3.4%p先前近期
- Protein purification and stability2.4%→5.7%+3.3%p先前近期
- Lipid Membrane Structure and Behavior0.0%→3.2%+3.2%p先前近期
- Crystallization and Solubility Studies0.0%→2.1%+2.1%p先前近期
- Ocular Surface and Contact Lens0.0%→2.1%+2.1%p先前近期
- Drug Solubulity and Delivery Systems19.4%→15.7%−3.7%p先前近期
- Antibiotics Pharmacokinetics and Efficacy2.8%→0.0%−2.8%p先前近期
- Diabetes Treatment and Management2.8%→0.0%−2.8%p先前近期
- Pharmacological Effects and Toxicity Studies2.4%→0.0%−2.4%p先前近期
- Extracellular vesicles in disease2.4%→0.0%−2.4%p先前近期
近期常見用語
近期論文標題中,比以往明顯增加的用詞。
作者國家分布
並列比較近 24 個月(2024-09 – 2026-08)與再往前 24 個月(2022-09 – 2024-08)的佔比。
- CN41.3%→23.0%−18.3%p先前近期
- DE12.0%→21.1%+9.1%p先前近期
- US15.1%→15.4%+0.3%p先前近期
- FI7.2%→9.5%+2.3%p先前近期
- GB5.5%→9.1%+3.5%p先前近期
- HU0.0%→7.8%+7.8%p先前近期
機構刊登數 Top 5
2018 – 2026 期間,在這本期刊發表論文最多的前 5 個機構。
最新刊登論文
20依刊登日期排序的最新 20 篇,並非完整清單。
高引用論文
202018 – 2026 期間被引用次數最多的 20 篇。
資料截至 2026-09-05